Charles E. Schmidt College of Medicine
Florida Atlantic University
777 Glades Road
Boca Raton, FL 33431



Professor of Integrated Medical Science

Tel. (561) 297-0252


John W. Newcomer, M.D. is Professor of Integrated Medical Science at the Charles E. Schmidt College of Medicine at Florida Atlantic University (FAU). Dr. Newcomer has served as a principal investigator on research grants funded through the National Institutes of Health (NIH) for over 20 years, and has held a series of research leadership positions at Washington University in St. Louis, the University of Miami in Florida, and at FAU where he served as a Vice Dean in the medical school and in 2014 as Interim Vice President for Research for the university. Dr. Newcomer has received a number of honors and awards, including an Independent Scientist Award from the NIH and placement on the Thomson Reuters List of Highly Cited Researchers in 2014. Dr. Newcomer has served on the Board of Directors for the American Society of Clinical Psychopharmacology since 2006, serves as a longstanding reviewer for the NIH and other funding agencies, and since 2007 has been a member of the Metabolic Disorders Steering Committee of the Biomarkers Consortium of the Foundation for the National Institutes of Health (FNIH). In the public sector, for 13 years he was Chair of the Medicaid Drug Utilization Review Board for the State of Missouri, supporting public oversight for over $1B in pharmacy program expenditures.

  • 1981: A.B., Philosophy of Science, Magna Cum Laude, Brown University, Providence, RI.
  • 1985: M.D., Wayne State University School of Medicine, Detroit, MI. 
  • 1984: Visiting Medical Student, Department of Psychiatry, Yale University School of Medicine, New Haven, CT.
  • 1984: Visiting Medical Student, Langley Porter Psychiatric Institute, University of California at San Francisco, School of Medicine, San Francisco, CA.
  • 1988-1990: Research Fellowship in Psychiatry, Stanford University School of Medicine, Department of Veterans Affairs Medical Center (VAMC), Palo Alto, CA
  • 1986-1989: Residency in Psychiatry, Stanford University School of Medicine, Stanford, CA
  • 1985-1986: Internship in Internal Medicine, Sinai Hospital, Detroit, MI

  • 2016-2017: Vice Dean for Research and Innovation, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL
  • 2013-2016: Executive Vice Dean, Charles E. Schmidt College of Medicine, FAU
  • 2012-Present: Professor of Integrated Medical Science, Charles E. Schmidt College of Medicine, FAU
  • 2011-Present: Adjunct Professor of Psychiatry, WUSM
  • 2014-2015: Interim Vice President for Research, FAU
  • 2012-2013: Vice Dean for Research and Graduate Programs, Charles E. Schmidt College of Medicine,  FAU
  • 2011-2012: Leonard M. Miller Professor of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine, University of Miami, FL
  • 2011-2012: Senior Associate Dean for Clinical Research, Leonard M. Miller School of Medicine
  • 2011-2012: Director, Program on Complementary and Integrative Medicine, Leonard M. Miller School of Medicine
  • 2011: Ad Hoc Member, National Advisory Mental Health Council (NAMHC), National Institute of Mental Health (NIMH), National Institutes of Health (NIH)
  • 2008-2011: Gregory B. Couch Professor of Psychiatry, Psychology and Medicine, Washington University School of Medicine (WUSM)
  • 2007-2011: Director, Clinical Trials Unit (CTU), Institute for Clinical & Translational Science, WU
  • 2007-2011: Associate Director, Center for Applied Research Sciences (CARS), Institute for Clinical and Translational Science, ICTS, WU
  • 2007-2011: Co-Director, Regulatory Support Center (RSC), Institute for Clinical and Translational Science, ICTS, WU
  • 2006-2011: Medical Director, Center for Clinical Studies WUSM/WU
  • 2009-2010: Member, Interventions Committee on Adult Disorders (ITVA), NIMH, NIH
  • 2006-2009: Member, Interventions Committee for Schizophrenia Spectrum Disorders, Personality Disorders, and Disorders of Late Life (ITSP), NIMH, NIH
  • 2005-2011: Professor of Psychiatry, Psychology and Medicine WUSM/WU
  • 2003-2004: Member, Interventions (ITV) Initial Review Committee, NIMH, NIH
  • 2002-2005: Associate Professor of Psychology, (WU) (Joint appointment)
  • 2001-2004: Medical Officer; General Clinical Research Center (GCRC), WUSM
  • 2000-2005: Associate Professor of Psychiatry, WUSM (Primary appointment)
  • 1998-2004: Member, Bio-behavioral & Behavioral Processes (BBBP-2) Committee, Center for Scientific Review (CSR), NIH
  • 1997-2001: Adjunct Assistant Professor of Psychology, WU (Joint appointment)
  • 1992-2000: Assistant Professor of Psychiatry, WUSM (Primary appointment)
  • 1992-1997: Awardee, Scientist Development Award (MH01045), NIMH
  • 1990-1992: Instructor of Psychology, WU (Joint appointment)
  • 1997-2003: Awardee, Independent Scientist Award (MH01510), NIMH
  • 1997-2011: Chairman, Medicaid Drug Utilization Review (DUR) Board, Missouri Department of Social Services, Division Instructor, Department of Psychiatry, WUSM
  • Nasrallah H, Newcomer JW, Stankovic S, Risinger R, Du Y, Zummo J, Layne JE, Bose A, Silverman B, Ehrich EW: Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles, and Related Safety Considerations in Acute Schizophrenia. Journal of Clinical Psychiatry. 2016 Aug 30. PMID: 27574838
  • Lenze EJ, Farber NB, Kharasch E, Schweiger J, Yingling M, Olney J, Newcomer JW: Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: a pilot randomized controlled trial. World Journal of Biological Psychiatry. 2016 Feb 26:1-9. PMCID: PMC4905687
  • Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, Dew MA, Butters MA, Stack JA, Begley AE, Reynolds CF 3rd: Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomized, double-blind, placebo-controlled trial. The Lancet. 2015 Dec 12;386(10011):2404-12. PMCID: PMC4690746
  • Mangurian C, Newcomer JW, Vittinghoff E, Creasman JM, Knapp P, Fuentes-Afflick E, Schillinger D. Diabetes Screening Among Underserved Adults With Severe Mental Illness Who Take Antipsychotic Medications. JAMA Intern Medicine. 2015 Dec 1;175(12):1977-9. PMID: 26551047
  • Nicol GE, Morrato EH, Johnson MC, Campagna E, Yingling MD, Pham V, Newcomer JW: Implementation of a glucose screening program based on diffusion of innovation theory methods. Psychiatric Services (2011); 62(1), 12-14. PMID: 21209293.
  • Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW: Metabolic testing rates in 3 state medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry (2010); 67(1):17-24. PMID: 20048219.
  • Mangurian C, Goss E, Newcomer JW: Metabolic screening, prevalence, and treatment preferences in predominantly Hispanic severely mentally ill. Psych Services. (2010); (61)11: 1162-1163.
  • Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW: Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. American Journal of Psychiatry (2009); 166(3):345-353; PMID: 19147694.
  • Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B: Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care, (2009); 32(6):1037-1042, PMCID: 2681020.
  • Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, Hibbeln JR, Alpert JE: Obesity among those with mental disorders: A National Institute of Mental Health meeting report. Am J Prev Med. (2009); 36(4):341-350, PMID: 19285199.
  • Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Leonova-Edlund J, Leong RW, Brecher M: A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine or risperidone. J Clin Psychiatry (2009); 70(4):487-499, PMCID: 3703648.
  • Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L’Italien GJ, Nys M, Carson WH, McQuade RD: A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. Journal of Clinical Psychiatry (2008); 69(7):1046-1056; PMID: 18605811.
  • Newcomer JW, Hennekens CH: Severe Mental Illness and Risk of Cardiovascular Disease. JAMA (2007), 298(15):1794-1796; PMID: 17940236.
  • Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs (2005), 19(1):1-93.
  • Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G: Abnormalities in glucose regulation during antipsychotic treatment in schizophrenia. Arch Gen Psychiatry (2002), 59:337-345.
  • Olney JW, Newcomer JW, Farber NB: NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res, (1999), 33(6):523-533.
  • Newcomer JW, Selke G, Melson AK, Hershey T, Craft S, Richards K, Alderson AL: Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Arch Gen Psychiatry, (1999), 56:527-533.
  • Newcomer JW, Farber N, Jevtovic-Todorovic V, Selke G, Melson A, Hershey T, Craft S, Olney J: Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology, (1999), 20(2):106-118.
  • Craft S, Newcomer JW, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y, Luby J, Dagogo-Jack A, Alderson A: Memory improvement following induced hyperinsulinemia in Alzheimer's Disease. Neurobiol Aging, (1996), 17:123-130.
  • Newcomer JW, Craft S, Hershey T, Askins K, Bardgett ME: Glucocorticoid-induced impairment in declarative memory performance in adult humans. J Neurosci, (1994), 14(4):2047-2053.

View Pubmed Feed ⇉

Current Grant Support

  • Principal Investigator: Otsuka America Pharmaceutical Co. LTD; an Investigator-Initiated Collaborative Project) A Multi-center Open-label Longitudinal Study with Depot Aripiprazole Once Monthly Evaluating Effects on 30-, 90- & 180-day Re‑hospitalization Rates Following Hospital Discharge in Participants with Schizophrenia; 6/2015-5/2018.
  • Principal Investigator: MV Horvitz-Lennon, M.D.; Collaborator:  J.W. Newcomer; (NIH R01 MH106682) Improving Value of Publicly Funded Mental Health Care;6/1/16-3/31/20.
  • Principal Investigator: C Mangurian; Collaborator:  J.W. Newcomer; (NIH R03 DK101857) Diabetes Screening and Care Received by the Mentally Ill in an Integrated System; 8/1/15-7/31/18.
  • Principal Investigator: C Mangurian; Mentor:  J.W. Newcomer; (NIMH K23 MH093689) Improving Metabolic Screening in Diverse Severely Mentally Ill Populations; 8/16/2012-7/31/2017
  • Principal Investigator: G. Nicol; Mentor:  J.W. Newcomer; (NIMH K23 MH092435) Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children; 12/24/10-11/30/2017

Past Support

  • Principal Investigator: R01 MH72912
  • Principal Investigator: R01 MH63985
  • Principal Investigator: R01 MH60395
  • Principal Investigator: K02 MH01510
  • Principal Investigator: R01 MH53363

Editorial boards

  • 2009-2013 Schizophrenia Bulletin
  • 2007-2010 Obesity
  • 2006-2010 Journal of Clinical Psychiatry
  • 2002-2007 Neuropsychopharmacology

 Honors and awards

  • 2014 Thomson Reuters Highly Cited Researcher
  • 1996-2012 Best Doctors in America
  • 2006- Distinguished Fellow, American Psychiatric Association
  • 2002 Gerald L. Klerman Award for Outstanding Clinical Research, NARSAD
  • 1985 Alpha Omega Alpha
  • 1981 Phi Beta Kappa

Last Modified 12/6/17